Impact of Sex Hormones on Human Skin Immunity in Health and Hidradenitis Suppurativa (SIAP)
NCT ID: NCT07291193
Last Updated: 2026-01-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
240 participants
OBSERVATIONAL
2026-01-31
2031-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Assessment of Alterations in Immune Function During Pregnancy and Post Parturition
NCT01200979
Evaluation of a Serology Diagnostic Kit for the Detection of Genital Mycoplasma in Pregnancy
NCT01281319
Impact of In Utero Exposure to Immunomodulatory Drugs on Neonatal Immune System Development
NCT07033663
Maternal Determinants of Immunity to Influenza
NCT06716567
Epidemiology of Sexually Transmitted Infections and Its iMpAcT on fEmale Infertility
NCT05244967
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Pregnancy represents a unique physiological state of profound hormonal remodeling. In late pregnancy, maternal levels of estrogens, progesterone, and other hormones increase dramatically, offering an unparalleled model to study the impact of sex hormones on skin immunity. Understanding maternal skin immunity is of particular importance, as the maternal immune system must balance tolerance to the fetus with protection against pathogens. Perturbation in this balance can have lasting effects on both maternal and child health. Faced with the dramatic increase in inflammatory and autoimmune disorders affecting children globally, understanding maternal immunity is of fundamental importance.
Hidradenitis suppurativa (HS) provides a clinically relevant disease model to examine how sex hormones modulate skin inflammation. HS is a chronic inflammatory skin disease with strong sex dimorphism: it affects predominantly women (70%) in Europe but is often more severe in men. In women, HS severity varies with the menstrual cycle and is frequently altered during pregnancy, suggesting a hormonal component in disease modulation. Yet, the mechanisms linking sex hormones, pregnancy, and skin immune responses in HS remain unexplored.
By systematically comparing men, non-pregnant women, and pregnant women, in both health and HS, this study will map immune cell populations in the skin and determine how sex hormones; testosterone, estrogens, and progesterone; shape cutaneous immunity at steady state and during inflammation.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Healthy - Pregnant women
Adult woman, not affected by Hidradenitis Suppurativa, pregnant in her third trimester
Blood sample, skin microbiota and biopsy
Blood sample (maximum 40mL) Skin microbiota (collection of cells from the skin surface using a swab (non-invasive) Skin biopsy, in hormone-dependent areas and/or in a non-hormone-dependent areas
Healthy - Non-pregnant women
Adult woman, not affected by Hidradenitis Suppurativa
Blood sample, skin microbiota and biopsy
Blood sample (maximum 40mL) Skin microbiota (collection of cells from the skin surface using a swab (non-invasive) Skin biopsy, in hormone-dependent areas and/or in a non-hormone-dependent areas
Healthy - Men
Adult men, not affected by Hidradenitis Suppurativa
Blood sample, skin microbiota and biopsy
Blood sample (maximum 40mL) Skin microbiota (collection of cells from the skin surface using a swab (non-invasive) Skin biopsy, in hormone-dependent areas and/or in a non-hormone-dependent areas
Hidradenitis suppurativa - Pregnant women
Adult woman, affected by Hidradenitis Suppurativa, pregnant in her third trimester
Blood sample, skin microbiota and biopsy
Blood sample (maximum 40mL) Skin microbiota (collection of cells from the skin surface using a swab (non-invasive) Skin biopsy, in hormone-dependent areas and/or in a non-hormone-dependent areas
Hidradenitis suppurativa - Non-pregnant women
Adult woman, affected by Hidradenitis Suppurativa
Blood sample, skin microbiota and biopsy
Blood sample (maximum 40mL) Skin microbiota (collection of cells from the skin surface using a swab (non-invasive) Skin biopsy, in hormone-dependent areas and/or in a non-hormone-dependent areas
Hidradenitis suppurativa - Men
Adult men, affected by Hidradenitis Suppurativa
Blood sample, skin microbiota and biopsy
Blood sample (maximum 40mL) Skin microbiota (collection of cells from the skin surface using a swab (non-invasive) Skin biopsy, in hormone-dependent areas and/or in a non-hormone-dependent areas
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blood sample, skin microbiota and biopsy
Blood sample (maximum 40mL) Skin microbiota (collection of cells from the skin surface using a swab (non-invasive) Skin biopsy, in hormone-dependent areas and/or in a non-hormone-dependent areas
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject\>18 years and \<45 years,
* Written informed consent of the subject,
* Subject affiliated to the Assurance Maladie (French Health System) except Aide Médicale d'Etat (French State Medical Aid),
* Subject agrees that genomic analyses may be carried out on the samples
* Specific criteria :
* For pregnant women:Third trimester of pregnancy (between 29-37 weeks of amenorrhea).
* For HS subjects: Subject with hidradenitis suppurativa lesions at the sampling sites.
Exclusion Criteria
* Subject immunocompromised,
* Subject under legal protection (guardianship or curatorship),
* Subject is unable to provide informed consent and to comply with the study requirements due to geographical, social, or psychiatric reasons,
* Subject in other research whose procedures may influence the immune system,
* Contraindication to any of medications listed in section 5.1 (antiseptic and local anesthetic used for biopsy(ies)),
* Subject whose health condition does not permit participation in study procedures.
* Specific criteria :
* For no HS subjects : Scarred skin at the biopsy site, Subject with pre-existing and/or still active inflammatory skin conditions, Subject experiencing early menopause (women) or andropause (men).
18 Years
45 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institut Pasteur
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bénédicte OULES, MD-PhD
Role: PRINCIPAL_INVESTIGATOR
Assistance Publique - Hôpitaux de Paris
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2025-A00923-46
Identifier Type: OTHER
Identifier Source: secondary_id
2024-072
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.